Raleigh News Now

Global Injectable Drug Delivery Market will be worth USD 789.7 billion by 2024 – New market report by Data Bridge Market Research

Global Injectable Drug Delivery Market will be worth USD 789.7 billion by 2024 – New market report by Data Bridge Market Research

Global Injectable Drug Delivery Market is expected to grow at 11.5% in the forecast period 2017 to 2024
Global Injectable Drug Delivery Market, By Type (Devices {Conventional Injection, Self-Injection}, Formulations {Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations}, Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology), Usage Pattern (Curative Care, Immunizations), Mode of Administration (Skin, Circulatory, Organs, Central Nervous System), End User, Geography – Industry Trends and Forecast to 2024

Global injectable drug delivery is expected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024.

Global injectable drug delivery market is segmented based on product type, applications, mode of administration, usage pattern, end-user and geography.

On the basis of type the market is further segmented into Devices and formulation. Devices are further segmented into Conventional Injection, Self-Injection whereas Formulations are further segmented into Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations.

For Sample Report: Global Injectable Drug Delivery Market – Industry Trends and Forecast to 2024

Based on Application the market is further segmented into Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology.

Based on Usage Pattern the market is further segmented into Curative Care, Immunizations.

Based on Mode of Administration the market is further segmented into Skin, Circulatory, Organs, Central Nervous System.

Based on End User the market is further segmented into Hospitals & Clinics, Home Care Settings, Research Laboratories,  Pharma & Biotech Companies

 

To read more about the scope and findings of this report visit: Global Injectable Drug Delivery Market Is Growing At A Significant Rate In The Forecast Period 2017-2024

 

Based on geography the Injectable Drug Delivery Market is segmented into North & South America, Europe, Asia-Pacific and, Middle East & Africa. North America is expected to dominate the market for Injectable Drug Delivery in 2016 and expected to be growing with highest CAGR in the forecast period 2017 – 2024.The report of this market shares countries such as U.S., Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among other companies.

KEY PLAYERS OPERATING IN GLOBAL INJECTABLE DRUG DELIVERY MARKET:

  • Baxter International, Inc.
  • Becton Dickinson and Company
  • Gerresheimer AG
  • Pfizer, Inc.
  • Schott AG
  • Alkermes Plc.,
  • Eli Lilly and Company
  • Sandoz
  • Terumo Corporation
  • Teva Pharmaceuticals Industries Ltd.
  • Bespak
  • Antares Pharma
  • Elcam Medical,
  • Haselmeier, Mylan N.V.
  • Novo Nordisk
  • Owen Mumford Ltd
  • Sanofi
  • West Pharmaceutical Services, Inc
  • Ypsomed Holding AG

Enquire about the report: Global Injectable Drug Delivery Market – Industry Trends and Forecast to 2024

Table of Content:

1. INTRODUCTION

       1.1. OVERVIEW OF THE INJECTABLE DRUG DELIVERY MARKET

       1.2. MARKET SEGMENTATION & COVERAGE

                1.2.1. CURRENCY AND PRICING

                1.2.2. LIMITATION

                1.2.3. STAKEHOLDERS

2. RESEARCH METHODOLOGY

       2.1. KEY TAKEAWAYS

       2.2. ARRIVING AT THE INJECTABLE DRUG DELIVERY MARKET SIZE

                2.2.1. MARKET CRACKDOWN APPROACH

                2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS

                2.2.3. DATA TRIANGULATION

                2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES

                2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES

                2.2.6. PORTER’S FIVE FORCES MATRIX

       2.3. GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT

       2.4. ASSUMPTIONS

3. MARKET LANDSCAPE SUMMARY

4. PREMIUM INSIGHTS

       4.1. OVERVIEW

       4.2. INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS

       4.3. MARKET OVERVIEW

                4.3.1. DRIVERS

                           4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASES

                           4.3.1.2. INCRESING DEMAND OF SELF INJECTION DEVICES

                           4.3.1.3. GROWTH OF BILOGICS AND BIOSIMILARS MARKET

                           4.3.1.4. TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY MARKET

                4.3.2. RESTRAINTS

                4.3.3. OPPORTUNITIES

                           4.3.3.1. INCRESING DEMAND FOR GENERIC INJECTABLES

                4.3.4. THREATS

                           4.3.4.1. PRODUCT RECALLS

                           4.3.4.2. REGULATORY HURDLES

                           4.3.4.3. STABILITY OF PRODUCTS

                           4.3.4.4. STERILITY OF INJECTIONS

                           4.3.4.5. GROWING DEMAND OF OTHER DRUG DELIVERY TECHNOLOGIES

       4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES

5. INJECTABLE DRUG DELIVERY MARKET, BY TYPE

       5.1. OVERVIEW

       5.2. INJECTABLE DRUG DELIVERY DEVICES

       5.3. INJECTABLE DRUG DELIVERY FORMULATIONS

6. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE

       6.1. OVERVIEW

       6.2. CONVENTIONAL INJECTION DEVICES

                6.2.1. BY MATERIAL

                           6.2.1.1. GLASS

                           6.2.1.2. PLASTIC

                6.2.2. BY PRODUCT

                           6.2.2.1. EMPTY SYRINGES

                           6.2.2.2. PREFILLED SYRINGES

                6.2.3. BY USABLITY

                           6.2.3.1. REUSABLE SYRINGES

                           6.2.3.2. DISPOSABLE SYRINGES

       6.3. SELF INJECTION DEVICES

                6.3.1. NEEDLE FREE INJECTORS

                           6.3.1.1. BY PRODUCT

                                         6.3.1.1.1. EMPTY NEEDLE FREE INJECTORS

                                         6.3.1.1.2. PREFILLED NEEDLE FREE INJECTORS

                            6.3.1.2. BY TECHNOLOGY

                                         6.3.1.2.1. JET BASED NEEDLE FREE INJECTORS

                                         6.3.1.2.2. SPRING BASED NEEDLE FREE INJECTORS

                                         6.3.1.2.3. LASER POWERED NEEDLE FREE INJECTORS

                                         6.3.1.2.4. VIBRATION BASED NEEDLE FREE INJECTORS

                           6.3.1.3. BY USABILITY

                                         6.3.1.3.1. REUSABLE NEEDLE FREE INJECTORS

                                         6.3.1.3.2. DISPOSABLE NEEDLE FREE INJECTORS

                6.3.2. AUTOINJECTORS

                           6.3.2.1. BY PRODUCT

                                         6.3.2.1.1. EMPTY AUTOINJECTORS

                                         6.3.2.1.2. PREFILLED AUTOINJECTORS

                           6.3.2.2. BY TECHNOLOGY

                                         6.3.2.2.1. AUTOMATED AUTOINJECTORS

                                         6.3.2.2.2. MANUAL AUTOINJECTORS

                           6.3.2.3. BY DESIGN

                                         6.3.2.3.1. STANDARDIZED AUTOINJECTORS

                                         6.3.2.3.2. CUSTOMIZED AUTOINJECTORS

                           6.3.2.4. BY USABILITY

                                         6.3.2.4.1. REUSABLE AUTOINJECTORS

                                         6.3.2.4.2. DISPOSABLE AUTOINJECTORS

                6.3.3. PEN INJECTORS

                           6.3.3.1. BY PRODUCT

                                         6.3.3.1.1. SINGLE CHAMBERED PEN INJECTORS

                                         6.3.3.1.2. DUAL CHAMBERED PEN INJECTORS

                           6.3.3.2. BY DESIGN

                                         6.3.3.2.1. STANDARDIZED PEN INJECTORS

                                         6.3.3.2.2. CUSTOMIZED PEN INJECTORS

                           6.3.3.3. BY USABILITY

                                         6.3.2.3.1. REUSABLE PEN INJECTORS

                                         6.3.2.3.2. DISPOSABLE PEN INJECTORS

                6.3.4. WEARABLE INJECTORS

                6.3.5. OTHER INJECTABLE DEVICES

7. INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE

       7.1. OVERVIEW

       7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS

                7.2.1. SOLUTIONS

                7.2.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS

                7.2.3. SUSPENSIONS

                7.2.4. EMULSIONS

       7.3. NOVEL DRUG DELIVERY FORMULATIONS

                7.3.1. COLLOIDAL DISPERSIONS

                           7.3.1.1. LIPOSOMES

                           7.3.1.2. NIOSOMES

                           7.3.1.3. POLYMERIC MIXED MICELLES

                           7.3.1.4. NANOPARICLES

                                         7.3.1.4.1. NANOSUSPENSIONS

                                         7.3.1.4.2. NANOEMULSIONS/MICROEMULSIONS

                                         7.3.1.4.3. SOLID LIPID NANOPARTICLES

                7.3.2. MICROPARTICLES

                           7.3.2.1. MICROSPHERES

                           7.3.2.2. MICROCAPSULES

                7.3.3. LONG ACTING INJECTION FORMULATIONS

8. INJECTABLE DRUG DELIVERY MARKET, BY APPLICATIONS

       8.1. OVERVIEW

       8.2. AUTOIMMUNE DISEASES

                8.2.1. RHEUMATOID ARTHRITIS

                8.2.2. MULTIPLE SCLEROSIS

                8.2.3. CHRON’S DISEASE

                8.2.4. PSORIASIS

                8.2.5. OTHER AUTOIMMUNE DISEASES

       8.3. HORMONAL DISORDERS

                8.3.1. DIABETES

                8.3.2. ANEMIA

                8.3.3. REPRODUCTIVE HEALTH DISEASE

                8.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY

                8.3.5. OSTEOPOROSIS

                8.3.6. GROWTH HORMONE DEFICIENCY (GHD)

       8.4. ORPHAN DISEASES

       8.5. ONCOLOGY

       8.6. OTHERS

                8.6.1. PAIN MANAGEMENT

                8.6.2. ALERGY TREATMENT

                8.6.3. AESTHETIC TREATMENTS

                8.6.4. HEPATITIS C

                8.6.5. HEMOPHILIA

9. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

       9.1. OVERVIEW

       9.2. CURATIVE CARE

       9.3. IMMUNIZATIONS

       9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)

10. INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

       10.1. OVERVIEW

       10.2. SKIN

       10.3. CIRCULATORY/MUSKOSKELETAL

       10.4. ORGANS

       10.5. CENTRAL NERVOUS SYSTEM

11. INJECTABLE DRUG DELIVERY MARKET, BY END USER

       11.1. OVERVIEW

       11.2. HOSPITALS AND CLINICS

       11.3. HOME HEALTHCARE SETTINGS

       11.4. RESEARCH LABORATORIES

       11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES

       11.6. OTHER END USERS

12. INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY

       12.1. COUNTRYWISE  INJECTABLE DRUG DELIVERY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

                12.1.1. NORTH AMERICA

                                         12.1.1.1. U.S.

                                         12.1.1.2. CANADA

                                          12.1.1.3. MEXICO

                12.1.2. EUROPE

                                         12.1.2.1. GERMANY

                                         12.1.2.2. FRANCE

                                         12.1.2.3. U.K.

                                         12.1.2.4. ITALY

                                         12.1.2.5. SPAIN

                                         12.1.2.6. RUSSIA

                                         12.1.2.7. TURKEY

                                          12.1.2.8. BELGIUM

                                         12.1.2.9. NETHERLANDS

                                          12.1.2.7. SWITZERLAND

                                         12.1.2.8. REST OF EUROPE

                12.1.3. ASIA-PACIFIC (APAC)

                                         12.1.3.1. JAPAN

                                         12.1.3.2. CHINA

                                         12.1.3.3. SOUTH KOREA

                                         12.1.3.4. INDIA

                                         12.1.3.5. AUSTRALIA

                                         12.1.3.6. SINGAPORE

                                         12.1.3.7. THAILAND

                                         12.1.3.8. MALAYSIA

                                         12.1.3.9. INDONESIA

                                         12.1.3.10. PHILIPPINES

                                         12.1.3.11. REST OF APAC

                12.1.4. LATIN AMERICA

                                         12.1.4.1. BRAZIL

                                         12.1.4.2. REST OF LATIN AMERICA

                12.1.5. MIDDLE EAST AND AFRICA

                                         12.1.5.1. SOUTH AFRICA

                                         12.1.5.2. REST OF MIDDLE EAST AND AFRICA

       12.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

13. INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE

       13.1. GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.4. APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.6. MIDDLE EAST AND AFRICA  INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.7. MERGERS & ACQUISITIONS

       13.8. NEW PRODUCT DEVELOPMENT & APPROVALS

       13.9. EXPANSIONS

       13.10. REGULATORY CHANGES

       13.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

14. INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES

       14.1. BAXTER INTERNATIONAL, INC.

                14.1.1. OVERVIEW

                14.1.2. SWOT ANALYSIS

                14.1.3. PRODUCT PORTFOLIO

                14.1.4. REVENUE ANALYSIS

                14.1.5. ANALYSTS VIEW

       14.2. BECTON, DICKINSON AND COMPANY

                14.2.1. OVERVIEW

                14.2.2. SWOT ANALYSIS

                14.2.3. PRODUCT PORTFOLIO

                14.2.4. REVENUE ANALYSIS

                14.2.5. ANALYSTS VIEW

       14.3. GERRESHEIMER, AG

                14.3.1. OVERVIEW

                14.3.2. SWOT ANALYSIS

                14.3.3. PRODUCT PORTFOLIO

                14.3.4. REVENUE ANALYSIS

                14.3.5. ANALYST VIEW

       14.4. PFIZER, INC.

                14.4.1. OVERVIEW

                14.4.2. SWOT ANALYSIS

                14.4.3. PRODUCT PORTFOLIO

                14.4.4. REVENUE ANALYSIS

                14.4.5. ANALYSTS VIEW

       14.5. SCHOTT AG

                14.5.1. OVERVIEW

                14.5.2. SWOT ANALYSIS

                14.5.3. PRODUCT PORTFOLIO

                14.5.4. REVENUE ANALYSIS

                14.5.5. ANALYSTS VIEW

       14.6. ALKERMES PLC

                14.6.1. OVERVIEW

                14.6.2. SWOT ANALYSIS

                14.6.3. PRODUCT PORTFOLIO

                14.6.4. REVENUE ANALYSIS

                14.6.5. ANALYSTS VIEW

       14.7. ELI LILLY AND COMPANY

                14.7.1. OVERVIEW

                14.7.2. SWOT ANALYSIS

                14.7.3. PRODUCT PORTFOLIO

                14.7.4. REVENUE ANALYSIS

                14.7.5. ANALYSTS VIEW

       14.8. SANDOZ

                14.8.1. OVERVIEW

                14.8.2. SWOT ANALYSIS

                14.8.3. PRODUCT PORTFOLIO

                14.8.4. REVENUE ANALYSIS

                14.8.5. ANALYSTS VIEW

       14.9. TERUMO CORPORATION

                14.9.1. OVERVIEW

                14.9.2. SWOT ANALYSIS

                14.9.3. PRODUCT PORTFOLIO

                14.9.4. REVENUE ANALYSIS

                14.9.5. ANALYSTS VIEW

       14.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.

                14.10.1. OVERVIEW

                14.10.2. SWOT ANALYSIS

                14.10.3. PRODUCT PORTFOLIO

                14.10.4. REVENUE ANALYSIS

                14.10.5. ANALYSTS VIEW

15. APPENDIX

       15.1. RELATED REPORTS

       15.2. CUSTOMIZABLE OPTIONS

       15.3. SOURCE SHEET

       15.4. BIBLIOGRAPHY

16. ABOUT DATA BRIDGE MARKET RESEARCH


About Data Bridge Market Research:

Data Bridge is an organization lead by well versed forecasters, analysts and researchers who indulge in detailed and diligent research on different markets, trends and emerging opportunities in the successive direction to cater to your business needs. Data Bridge aims to make your organization well acquainted with profound knowledge of the global and local market statistics.

Related Reports:

Global Radiopharmaceuticals Market – Industry Trends and Forecast to 2024

By Type (Diagnostic, Therapeutic), Procedural Volumes (Diagnostic Procedures, Therapeutic Procedures), Application, Sources (Nuclear Reactors, Cyclotrons), End User, Geography (North America, Europe, APAC, South America, MEA)– Industry Trends andForecast To 2024

Media Contact
Company Name: Data Bridge Market Research Private Limited
Contact Person: Varsha Chaudhari
Email: Send Email
Phone: +1-888-387-2818
Address:Office Number 317, Amanora Chambers, Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/